Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 8/20 | 0.54 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.54 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10533356 | 0.93 | PDE10A (0.52) | CYSLTR1CYSLTR2GPBAR1PDE10AALOX5 | |
| SCHEMBL7454262 | 0.85 | PDE10A (0.57) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL27816007 | 0.81 | CYSLTR1 (0.51) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL19337404 | 0.80 | ALOX5 (0.52) | CYSLTR1CYSLTR2GPBAR1ALOX5 | |
| SCHEMBL6582909 | 0.78 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL7452392 | 0.78 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL7716689 | 0.77 | PDE10A (0.63) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL12404424 | 0.77 | CYSLTR1 (0.52) | CYSLTR1CYSLTR2GPBAR1PDE10AALOX5 | |
| SCHEMBL7714623 | 0.76 | CYSLTR1 (0.56) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL7717028 | 0.76 | CYSLTR1 (0.56) | CYSLTR1CYSLTR2GPBAR1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1030665-A4 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | AVENTIS PHARM PROD INC (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-1030665-A1 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | Aventis Pharmaceuticals Products Inc. (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999020275-A1 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |